Cytori Therapeutics, Inc. (NASDAQ:CYTX) closed its last session at $0.38. The stock traded within a range of $0.340 and $0.420. The company operates in the Healthcare sector with a market capitalization of 7690. Trading volume for Cytori Therapeutics, Inc. was 6.84 Million in its previous trading session. Currently, Cytori Therapeutics, Inc. (NASDAQ:CYTX) has an average volume of 1.17 Million.
Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company’s preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patient’s own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients.
Cytori Therapeutics, Inc. (NASDAQ:CYTX) received a Buy rating from 1 analysts. 0 analysts gave its stock an Outperform rating. 0 analysts say it’s a Hold while 0 analysts provided their expert opinion as Sell.
Cytori Therapeutics, Inc. (NASDAQ:CYTX) touched its 1-Year High price of $2.130 on 02/15/17 and its 1-Year Low price of $0.220 on 12/15/17.
EPS & Financials
Cytori Therapeutics, Inc. (NASDAQ:CYTX) reported its EPS in the last quarter as $-0.14/Share beating the analyst estimate of $-0.16/Share by a difference of $0.02. This showed a surprise of 12.5% in the last quarter earnings.
For the current quarter, 3 analysts are projecting a mean EPS of $-0.06/share. According to their observations and findings, the stock could provide a high EPS of $-0.04/share and a low EPS of $-0.07/share.
Analysts believe that the company has the potential to earn average revenue of $2.74 Million for the current quarter. According to their predictions high & low revenue estimates are 3.5 Million and 2 Million respectively.
By taking a look at the stock’s current statistics it can gauged that the stock candle is BULLISH with HIGH volatility. Cytori Therapeutics, Inc. (NASDAQ:CYTX) has a 20-Day average volume of 1.98 Million. According to today’s trading volume Cytori Therapeutics, Inc. is ABOVE its 20-Day Avg. volume with the stock showing ABOVE Abnormal volume in the past 150 days.
Moving average convergence divergence (MACD) shows that the stock is on a PRICE RELATIVITY trend. The trend for the past 10-days shows that the company was in BULLISH territory while an analysis of the last 40-Day trend shows a BEARISH signal. The 100-Day trend also shows a BEARISH trend as well.
The company currently has an insider ownership of 3.97 Percent and Institutional ownership of 7.4 Percent. The return on assets stands at -75.6%, Return on Equity currently is -249.4% and the Return on Investment value is -68.9%.
Cytori Therapeutics, Inc. (NASDAQ:CYTX) gross margin percentage stands at 63.9% while its operating margin for the past trailing twelve month is 0 percent and its overall profit margin (ttm) is 0 Percent. The stock is currently moving above its 20-Day Simple Moving Average of 34.4% with a 50-Day Simple Moving Average of 16.62 percent. As of today, the company has a SMA200 (200-day simple moving average) of -43.02 Percent. The Stock has YTD (year to date) performance of 26.23 percent.
The TTM operating margin for the company stands at 0%. The return on invested capital is at -68.9%, which is good, compared to its peers. The Free Cash Flow or FCF margin is 0.
The company’s stock is currently moving with a -ve distance from the 200 day SMA of approximately -43.02%, and has a solid year to date (YTD) performance of 26.23% which means that the stock is constantly adding to its value from the previous fiscal year end price.